{
  "id": 12899122,
  "title": "Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform",
  "url": "https://urgent.news/2026/10/08/eli-lillys-obesity-business-could-become-a-much-bigger-healthcare",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-08T15:53:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/eli-lillys-obesity-business-could-become-much-bigger-healthcare-platform"
  },
  "original_language": "en",
  "account": null,
  "summary": "Eli Lilly (NYSE: LLY) is trying to turn blockbuster obesity drugs into something much bigger. Its path to $1,500 depends on whether new medicines, additional indications, manufacturing scale, and rising patient volumes can generate durable earnings sufficient to overcome pricing",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Eli Lilly's Obesity Business Could Become a Much Bigger Healthcare Platform",
        "url": "https://urgent.news/2026/10/08/eli-lillys-obesity-business-could-become-a-much-bigger-healthcare-12905552",
        "published": "2026-10-08T15:33:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}